

**ASX & Media Release**

## **Patrys Awarded Grant for Lead Clinical Candidate**

- **Development of lead product PAT-SM6 to benefit from federal ARC grant**
- **Financial support for collaboration with leading experts at the University of Melbourne**
- **First-in-human clinical trial for PAT-SM6 expected to commence this calendar year**

**Melbourne, Australia; 11 November, 2009:** Patrys Limited (ASX: PAB), a leader in the development of novel and safe treatments for cancers with high mortality rates, announced today that scientific collaborators at the University of Melbourne have been awarded a \$300,000 grant to support the development of Patrys' lead clinical candidate PAT-SM6.

PAT-SM6 is a natural human antibody that has shown great promise for the treatment of solid tumours and metastases in a number of cancer applications, including melanoma, pancreatic cancer and gastric cancer.

A first-in-human clinical trial for PAT-SM6 is scheduled for this calendar year.

The grant, which has been awarded by the Australian Government's Australian Research Council ("ARC"), will provide funding to further evaluate the mechanism by which PAT-SM6 kills cancer cells, which in turn can lead to improved opportunities for successful clinical development.

Competition for these grants is significant and each submission is subject to a detailed review by independent scientific experts in the respective field of science.

"Patrys is fortunate to receive support from the Australian federal government, as it provides financial assistance while simultaneously bringing independent validation of the value of our products," said Patrys CEO, Mr Dan Devine.

The project, which will commence in early 2010, will be led by Associate Professor Geoff Howlett, Dr Terry Mulhern and Dr Danny Hatters, University of Melbourne researchers with extensive experience in their respective fields of science. These researchers, along with Patrys R&D colleagues who will support the project, are all located at Melbourne's leading biotechnology research centre, the Bio21 Institute in Parkville.

"We are very excited about working with Patrys to gain a better understanding of the characteristics of PAT-SM6, including the unique mechanism by which PAT-SM6 kills cancer cells," said Associate Professor Howlett.



“Looking forward, this is also a great opportunity to deepen our ties with the local research community, which is well qualified to assist Patrys in the advancement of our anti-cancer product pipeline,” added Mr. Devine.

**-Ends-**

**For further information, please contact:**

***Patrys Limited:***

Daniel Devine  
Chief Executive Officer  
P: +61 3 9670 3273 or  
[info@patrys.com](mailto:info@patrys.com)

***Patrys Media:***

Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722 or  
[kwilliamson@bcg.com.au](mailto:kwilliamson@bcg.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).

**About PAT-SM6:**

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. PAT-SM6 binds to a proprietary cancer associated disease target that is expressed on the surface of cancer cells but not healthy tissues. Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of the patient’s cancer type, age, gender or disease stage. Patrys has filed patent applications to cover the PAT-SM6 molecule, its disease target, and its mechanism of action.

**About ARC:**

The Australian Research Council (ARC) is a statutory authority within the Australian Government's Innovation, Industry, Science and Research portfolio. The ARC advises the Government on research matters and manages the National Competitive Grants Program, a significant component of Australia's investment in research and development. The ARC Linkage programs help to broker partnerships between researchers and industry, government and community organisations, as well as the international community. The outcomes of ARC-funded research deliver cultural, economic, social and environmental benefits to all Australians.